Trial Profile
EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 May 2014
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Merck Serono; Pfizer